Twist Bioscience Corporation

Executive Summary

SELL, Medium conviction. TWST rates SELL, Medium conviction. The company just raised FY26 revenue guidance to $456M-$457M, Q3 revenue reached $118.4M with 23% YoY growth, and Q4 adjusted EBITDA breakeven is now the stated goal, but the stock sits 2.2% below its 52-week high after a 112.7% three-month run while still posting negative EPS and a mixed beat/miss record. The issue is not whether the business is improving, it is whether that improvement supports a $5.7B market cap and 15.76x P/S today. It does not.

Investment Thesis

TWST's business is getting better. The stock is the problem. Revenue growth has reaccelerated, gross margin is now above 52%, and management raised FY26 revenue guidance to $456M-$457M after a 23% YoY Q3. Therapeutics was especially strong at +49% YoY, with large tech and AI-discovery demand now showing up in orders, not just slideware. On the operating side, the company has extended its streak to 14 consecutive quarters of sequential revenue growth, launched complex genes commercially, and is building data characterization capacity around a broader AI-enabled workflow. Those are real signals of platform relevance.

But a good company can still be a bad stock at the wrong price. At $115.67, investors are paying 15.76x sales for a company that still posted FY2025 EPS of -1.30, FY2025 operating margin of -57.9%, and Q3 adjusted EBITDA of -$11.3M. The market is no longer underwriting an improving growth story. It is underwriting a fairly smooth path to durable profitability. That is a much higher standard, especially after the stock surged 112.67% in three months and now sits just 2.2% below its 52-week high.

The case against the stock depends on three things. First, valuation. TWST trades far above the peer 8.7x P/S average, despite having no meaningful P/E and still-negative cash economics. Second, execution quality is not spotless. The company missed EPS in 3 of the last 4 quarters, including a -44.9% miss in May 2026. Third, dilution is not hypothetical. TWST just sold $300M of stock, which helps liquidity but tells investors the self-funding model is not here yet.

What could prove this SELL wrong is obvious: if AI-enabled discovery keeps compounding at triple-digit order growth into FY27, if therapeutics remains near current growth levels, and if Q4 breakeven becomes the start of a sustained profit inflection rather than a one-quarter milestone, then today's valuation could hold. That path exists. It is just already priced like the hard part is done, when it is not.

Key Metrics

Financial Strength

The balance sheet is not the problem. Leverage is low at 0.21 debt/equity, total debt is just $0.1B, and the 2.70 current ratio suggests no near-term liquidity stress. The business is also showing genuine operating leverage, with FY2025 operating margin improving by 1,270 bps year over year and Q3 FY26 gross margin reaching 52.8%. The issue is that cash generation still has not crossed into clearly positive territory, and the recent $300M equity raise underscores that the company remains dependent on capital market access while it chases scale economics.

Competitive Position

TWST's edge is manufacturing and workflow depth, not just catalog breadth. The company has built automated DNA synthesis capacity, launched complex genes with 1,800+ constructs across 100+ orders, and is adding data characterization capacity to support a one-stop AI discovery workflow. That moat is durable if customers value speed, reproducibility, and integrated discovery services, but it is not impregnable because AI lowers design friction for the whole ecosystem and could shift bargaining power if synthesis becomes more commoditized.

Management & Guidance

Management's current message is specific and testable. CFO Adam Laponis said, "For fiscal '26, we are increasing our revenue guidance and now expect total revenue of $456 million to $457 million, up $12 million at the midpoint, representing growth of approximately 21% year-over-year." He also said, "For Q4 of fiscal 2026, we expect total revenue of $123 million to $124 million, growth of approximately 25% year-over-year at the midpoint," and, "While into our final quarter of the fiscal year, we remain confident in our trajectory and continue to expect to achieve adjusted EBITDA breakeven this quarter." That guidance is credible on revenue because the company has shown a long sequential growth streak and just beat its implied pace in Q3, but credibility is lower on bottom-line conversion because recent EPS delivery has been uneven and Q3 EBITDA was still -$11.3M.

Segment Analysis

• Therapeutics (Not disclosed): Q3 FY26 revenue grew 49% YoY, driven by pharma, dry lab biotech, and large tech AI-discovery demand.
• NGS applications / diagnostics (Not disclosed): Q3 FY26 grew 12% YoY and 8% QoQ, supported by diagnostics top accounts and MRD momentum.
• Industry & applied ($5.7M in Q3 FY26): Declined YoY from $6.1M to $5.7M, showing not all end markets are participating in the current strength.
• Geography (Not disclosed): No geographic split was provided in the supplied data, though management has emphasized domestic manufacturing with 100% of DNA made in the U.S. on the historical call.

Capital Allocation

Capital allocation has prioritized growth infrastructure over shareholder returns, which is sensible for the stage of the business but raises the bar on eventual returns. Buybacks and dividends are $0.0B, free cash flow is effectively $0.0B, and capex is shown as $0.0B in the supplied snapshot, while the company just completed an upsized $300M common equity offering. That deal improves flexibility, but it also confirms that dilution remains part of the funding model until operating cash generation is consistently positive.

Management Execution & Track Record

Management has delivered on growth and margin direction better than on clean earnings conversion. On the 2024 Q4 call, the company guided FY25 revenue to $367M-$377M, growth of 17%-20%, gross margin of 48% for FY25 and 50% in Q4 FY25, plus adjusted EBITDA loss of -$60M to -$65M. Actual FY2025 revenue came in at $0.4B, or roughly $400M, above that range, and FY2025 operating margin improved to -57.9% from -70.6%, while gross margin later reached 52.8% in Q3 FY26, so the margin expansion roadmap was directionally right. The current FY26 guide of $456M-$457M implies another step up to about 21% growth, and management now says, "While into our final quarter of the fiscal year, we remain confident in our trajectory and continue to expect to achieve adjusted EBITDA breakeven this quarter." The credibility issue is quarterly earnings consistency: the last four quarters include misses of -44.9%, -4.2%, and -10.6% against street EPS estimates, so management deserves credit on commercial execution but not a blank check on profitability timing.

Positioning & Flows

Positioning is hot and unstable. Institutional ownership is concentrated, with the top holders including Artisan, ARK, and BlackRock, while reported top-3 institutional ownership at 102.8% points to heavy lending, rehypothecation, or data quirks common in crowded names. Short interest is high at 23.65% of shares, or 14.1M shares with 8.1 days-to-cover, and the options regime is flagged positive, which helps explain the violent 26.35% one-week and 112.67% three-month move. That can keep the stock above fair value longer than fundamentals alone justify.

Bull Case

• FY26 revenue guidance was raised by $12M at the midpoint to $456M-$457M, implying about 21% YoY growth, after Q3 revenue of $118.4M, up 23% YoY.
• Gross margin reached 52.8% in Q3 FY26, above the FY26 target of greater than 52%, and management expects more than $5M of OpEx reduction in Q4 after roughly $2M of Q3 transition costs.
• Therapeutics revenue grew 49% YoY, and management said AI-enabled discovery should post triple-digit order growth in FY26 and potentially repeat triple-digit growth in FY27.
• Execution on revenue cadence has been durable, with the company reporting its 14th consecutive quarter of sequential revenue growth.

Bear Case

• The stock trades at 15.76x sales on FY25 revenue of just $0.4B, despite FY25 operating margin of -57.9% and net margin of -55.0%.
• Earnings quality remains weak, with misses in 3 of the last 4 quarters: -44.9% in May 2026, -4.2% in February 2026, and -10.6% in August 2026.
• Q3 adjusted EBITDA was still -$11.3M, or -23.6% margin, so the path from there to sustained profitability remains narrow even if Q4 reaches breakeven.
• The company just priced an upsized $300M equity offering, a reminder that dilution risk remains live while free cash flow is effectively $0.0B and profits are still negative.

Valuation & Price Target

Engine price target $95.03 (-17.8% vs current), Medium confidence.

• P/S Multiple: $83.38 (45% weight)
• Quality-adjusted: $121.22 (20% weight)

This view aligns with the quant baseline SELL and the engine price target of $95.03. The core reason is straightforward: even after acknowledging better fundamentals, including FY26 revenue guidance of $456M-$457M, Q3 gross margin of 52.8%, and a Q4 EBITDA breakeven target, the stock at $115.67 already discounts a more mature earnings profile than TWST currently has. The quality-adjusted method supports $121.22, which captures the improving business mix and AI optionality, but the simpler P/S method lands at $83.38 and better reflects that TWST still has negative EPS, a recent $300M equity raise, and a mixed earnings track record. Sell-side consensus is Strong Buy from 7 buy / 1 hold / 0 sell, but that is low-signal context here because the stock's current valuation leaves little room for any stumble.

Risk Assessment

Risk score 53/100 (Moderate). The biggest risk to a SELL is that AI-enabled drug discovery demand scales faster than expected, because therapeutics already grew 49% YoY and management expects triple-digit AI order growth in both FY26 and potentially FY27.

The Bottom Line

TWST rates SELL because the business improvement is real but already overcapitalized in the share price. A company guiding about 21% FY26 growth, with a plausible path to breakeven, does not obviously deserve 15.76x sales when EPS is still negative and dilution remains active. The near-term setup can stay volatile because of the 23.65% short interest and momentum-heavy positioning, so this is not a call for immediate collapse. What changes the view is sustained proof that Q4 breakeven is repeatable, not episodic, and that AI-driven demand can translate into durable positive free cash flow rather than just a higher revenue run rate.